158 related articles for article (PubMed ID: 34915632)
1. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].
Shan JQ; Nan SF; Li F; Shen CY; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632
[No Abstract] [Full Text] [Related]
2. Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models.
Jamali A; Ho N; Braun A; Adabi E; Thalheimer FB; Buchholz CJ
EMBO Mol Med; 2024 Apr; 16(4):784-804. PubMed ID: 38514793
[TBL] [Abstract][Full Text] [Related]
3. The Qi Yin San Liang San decoction enhances anti-CD19 CAR-T cell function in the treatment of B-cell lymphomas.
Dong S; Wang P; Zhang L; Zhang X; Li X; Wang J; Cui X; Lan T; Gao C; Shi Y; Wang W; Wang J; Jiang M
J Ethnopharmacol; 2024 Jan; 319(Pt 1):117109. PubMed ID: 37657771
[TBL] [Abstract][Full Text] [Related]
4. A major role for CD4
Boulch M; Cazaux M; Cuffel A; Ruggiu M; Allain V; Corre B; Loe-Mie Y; Hosten B; Cisternino S; Auvity S; Thieblemont C; Caillat-Zucman S; Bousso P
Cell Rep Med; 2023 Sep; 4(9):101161. PubMed ID: 37595589
[TBL] [Abstract][Full Text] [Related]
5. Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome.
Zheng N; Long Y; Bai Z; Li J; Wang H; Song DD; Liu HL; Shi JH; Zhao S
J Transl Med; 2024 Jan; 22(1):58. PubMed ID: 38221609
[TBL] [Abstract][Full Text] [Related]
6. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia.
Ma S; Wang Y; Qi K; Lu W; Qi Y; Cao J; Niu M; Li D; Sang W; Yan Z; Zhu F; Cheng H; Li Z; Zhao M; Xu K
Cancer Immunol Immunother; 2024 Apr; 73(6):104. PubMed ID: 38630258
[TBL] [Abstract][Full Text] [Related]
7. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy.
Zu C; Wu S; Zhang M; Wei G; Xu H; Cui J; Chang AH; Huang H; Hu Y
Cytotherapy; 2023 Nov; 25(11):1167-1175. PubMed ID: 37480884
[TBL] [Abstract][Full Text] [Related]
8. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
Ma S; Li H; Zhou D; Zhang X; Shi M; Cao J; Qi Y; Xia J; Liu Y; Wang X; Li D; Sang W; Yan Z; Zhu F; Sun H; Cheng H; Zheng J; Xu K; Li Z; Qi K; Wang Y
Cytotherapy; 2023 Jun; 25(6):653-658. PubMed ID: 36907717
[TBL] [Abstract][Full Text] [Related]
9. Cell-Based Models of 'Cytokine Release Syndrome' Endorse CD40L and Granulocyte-Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy.
Dibas A; Rhiel M; Patel VB; Andrieux G; Boerries M; Cornu TI; Alzubi J; Cathomen T
Cells; 2023 Nov; 12(21):. PubMed ID: 37947658
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy
Chen Y; Li R; Shang S; Yang X; Li L; Wang W; Wang Y
Front Immunol; 2021; 12():623610. PubMed ID: 34093519
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and side effects of anti-CD19 CAR T-cell therapy in patients with relapsed/refractory gastrointestinal lymphoma.
Jiang YL; Mu J; Cui R; Li X; Wang J; Li Q; Li J; Mou N; Deng Q
Cancer Med; 2024 Feb; 13(4):e7064. PubMed ID: 38457256
[TBL] [Abstract][Full Text] [Related]
12. [Study on construction of c-Met specific CAR-T cells and its killing effect on non-small cell lung carcinoma].
Min JT; Zhang L; Long CR; Fan HL; Li ZZ
Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):322-329. PubMed ID: 37078213
[No Abstract] [Full Text] [Related]
13. [Effect of signal peptide optimized by site-directed mutagenesis on the function of chimeric antigen receptor T cells].
Liu Y; Li F; Dai H; Zhou R; Wang M; Gan S; Xu Y
Sheng Wu Gong Cheng Xue Bao; 2024 Feb; 40(2):573-584. PubMed ID: 38369842
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies.
Manni S; Del Bufalo F; Merli P; Silvestris DA; Guercio M; Caruso S; Reddel S; Iaffaldano L; Pezzella M; Di Cecca S; Sinibaldi M; Ottaviani A; Quadraccia MC; Aurigemma M; Sarcinelli A; Ciccone R; Abbaszadeh Z; Ceccarelli M; De Vito R; Lodi MC; Cefalo MG; Mastronuzzi A; De Angelis B; Locatelli F; Quintarelli C
Nat Commun; 2023 Jun; 14(1):3423. PubMed ID: 37296093
[TBL] [Abstract][Full Text] [Related]
15. Enhancing brain entry and therapeutic activity of chimeric antigen receptor T cells with intra-arterial NEO100 in a mouse model of CNS lymphoma.
Wang W; He H; Zheng L; Zeng S; Cho HY; Kouhi A; Khawli LA; Chen L; Stathopoulos A; Schönthal AH; Epstein AL; Chen TC
J Neurosurg; 2024 Jun; 140(6):1549-1557. PubMed ID: 38157532
[TBL] [Abstract][Full Text] [Related]
16. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
[TBL] [Abstract][Full Text] [Related]
17. A novel safer CD19CAR with shRNA interference of IFN-γ can reduce multiple cytokine levels without significantly compromising its killing efficacy.
Zhang P; Ying P; Li H; Zhao N; Liu R; Li S; Xu W; Tang Y; Tang Y
Apoptosis; 2024 Apr; 29(3-4):556-567. PubMed ID: 38114800
[TBL] [Abstract][Full Text] [Related]
18. Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy.
Ding S; Chen R; Wang L; Zu C; Zhou X; Zhang J; Zhang M; Jin A; Wang T; Hu Y
BMC Cancer; 2023 Nov; 23(1):1055. PubMed ID: 37919691
[TBL] [Abstract][Full Text] [Related]
19.
Pfeiffer A; Thalheimer FB; Hartmann S; Frank AM; Bender RR; Danisch S; Costa C; Wels WS; Modlich U; Stripecke R; Verhoeyen E; Buchholz CJ
EMBO Mol Med; 2018 Nov; 10(11):. PubMed ID: 30224381
[TBL] [Abstract][Full Text] [Related]
20. Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect
Silvestre RN; Eitler J; de Azevedo JTC; Tirapelle MC; Fantacini DMC; de Souza LEB; Swiech K; Covas DT; Calado RT; Montero PO; Malmegrim KCR; Figueiredo ML; Tonn T; Picanço-Castro V
Front Immunol; 2023; 14():1226518. PubMed ID: 37818365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]